Enrolled patients were males, 18 years of age or older, with severe hemophilia A (FVIII activity ≤1 IU/dL), continuously treated with prophylactic exogenous FVIII for six months or more and no history of detectable FVIII inhibitors. Here, F8 is linked to hemophilia A.